News + Resources
Keep up with the latest
Featured
Scribe Therapeutics Highlights Data Underpinning its Comprehensive Strategy Targeting Key Lipid Drivers of ASCVD at American Heart Association (AHA) Scientific Sessions 2025
November 17, 2025
Scribe Therapeutics Highlights Data Underpinning its Comprehensive Strategy Targeting Key Lipid Drivers of ASCVD at American Heart Association (AHA) Scientific Sessions 2025
November 17, 2025
Epigenetic editors are a gentler form of gene editing
February 24, 2025
The Economist
Epigenetic editors are a gentler form of gene editing
February 24, 2025
All Stories
News
Appointments and advancements
March 10, 2022
BioWorld
Read Now
Press Release
Appointments and advancements
March 10, 2022
BioWorld
Read Now
News
Management Tracks
March 10, 2022
BioCentury
Read Now
Press Release
Management Tracks
March 10, 2022
BioCentury
Read Now
Press Release
Scribe Therapeutics Appoints David Parrot as Chief Financial Officer and George Manning as Controller
March 9, 2022
Read Now
Press Release
Scribe Therapeutics Appoints David Parrot as Chief Financial Officer and George Manning as Controller
March 9, 2022
Read Now
News
Big Pharma is waking up to the booming field of gene editing. Here are the top 18 biotechs to know in 2022 that are poised to grab the drug industry's attention.
January 31, 2022
Business Insider
Read Now
Press Release
Big Pharma is waking up to the booming field of gene editing. Here are the top 18 biotechs to know in 2022 that are poised to grab the drug industry's attention.
January 31, 2022
Business Insider
Read Now
News
Novel Gene Editing Systems Come Into Their Own
January 5, 2022
Genetic Engineering & Biotechnology News
Read Now
Press Release
Novel Gene Editing Systems Come Into Their Own
January 5, 2022
Genetic Engineering & Biotechnology News
Read Now
News
These gene-editing startups are aiming to solve one of CRISPR's biggest problems. Here's how they could upend biotech in 2022.
December 28, 2021
Business Insider
Read Now
Press Release
These gene-editing startups are aiming to solve one of CRISPR's biggest problems. Here's how they could upend biotech in 2022.
December 28, 2021
Business Insider
Read Now